Raymond James Financial Inc. Acquires 41,422 Shares of Boston Scientific Corporation $BSX

Raymond James Financial Inc. grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,177,337 shares of the medical equipment provider’s stock after buying an additional 41,422 shares during the period. Raymond James Financial Inc. owned approximately 0.15% of Boston Scientific worth $219,650,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Colonial Trust Co SC boosted its holdings in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 260 shares in the last quarter. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $25,000. Sunbeam Capital Management LLC bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the 1st quarter worth approximately $27,000. Finally, Ameriflex Group Inc. bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $31,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Down 1.0%

Shares of BSX opened at $103.15 on Monday. The business has a 50-day moving average of $103.56 and a 200 day moving average of $102.09. Boston Scientific Corporation has a fifty-two week low of $77.29 and a fifty-two week high of $108.94. The firm has a market cap of $152.84 billion, a P/E ratio of 61.40, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the firm posted $0.62 EPS. The firm’s revenue for the quarter was up 22.8% on a year-over-year basis. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BSX. Robert W. Baird increased their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Barclays increased their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Truist Financial increased their target price on Boston Scientific from $120.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. UBS Group increased their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Finally, Citigroup reiterated a “buy” rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $117.50.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 56,372 shares of Boston Scientific stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $18,347,824.96. The trade was a 24.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 345,029 shares of company stock worth $35,976,603. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.